• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Taxol hypersensitivity: rapid retreatment is safe and cost effective.

作者信息

Olson J K, Sood A K, Sorosky J I, Anderson B, Buller R E

机构信息

Division of Gynecologic Oncology, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242, USA.

出版信息

Gynecol Oncol. 1998 Jan;68(1):25-8. doi: 10.1006/gyno.1997.4906.

DOI:10.1006/gyno.1997.4906
PMID:9454655
Abstract

OBJECTIVE

The aim of this study was to describe a rapid retreatment strategy that is safe and cost effective in ovarian cancer patients with Taxol hypersensitivity reactions.

METHODS

A retrospective review of 91 women receiving Taxol-based chemotherapy at the University of Iowa Hospitals and Clinics between October 1991 and July 1996 was performed. All patients who developed hypersensitivity reactions to Taxol were identified and their treatment course and outcome were reviewed.

RESULTS

Seven women (7.7%) developed hypersensitivity reactions. All received standard premedications consisting of corticosteroids and histamine blockers. Six of the seven were rechallenged with the original Taxol solution starting at a slower rate. In these cases the infusion was completed within 24 h and none of these patients had a reaction in subsequent courses. One patient was not retreated due to the severity of her reaction during a 3-h infusion.

CONCLUSION

Retreatment with the original Taxol solution is safe and cost effective in most patients with hypersensitivity reactions. Retreatment with Taxol should be completed within 24 h. A schema for retreatment is presented.

摘要

相似文献

1
Taxol hypersensitivity: rapid retreatment is safe and cost effective.
Gynecol Oncol. 1998 Jan;68(1):25-8. doi: 10.1006/gyno.1997.4906.
2
[Taxol (paclitaxel) as second-line therapy in breast and ovarian cancer].
Harefuah. 1998 Apr 15;134(8):605-8, 671.
3
Hypersensitivity reactions in ovarian cancer patients receiving paclitaxel.
J Chemother. 1999 Oct;11(5):407-9. doi: 10.1179/joc.1999.11.5.407.
4
Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.紫杉醇相关过敏反应的静脉预防
Semin Oncol. 1997 Dec;24(6 Suppl 19):S19-13-S19-15.
5
A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel.两种预防紫杉醇过敏反应方案的比较
Gynecol Oncol. 2002 Mar;84(3):420-5. doi: 10.1006/gyno.2001.6546.
6
Single-dose dexamethasone paclitaxel premedication.单剂量地塞米松预处理紫杉醇。
Gynecol Oncol. 1998 May;69(2):122-4. doi: 10.1006/gyno.1998.4993.
7
Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy.
Cancer Chemother Pharmacol. 2005 Jul;56(1):91-6. doi: 10.1007/s00280-004-0924-9. Epub 2005 Mar 25.
8
Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments.对紫杉醇和多西他赛过敏反应的快速脱敏:用于77次成功治疗的新标准方案
Gynecol Oncol. 2005 Mar;96(3):824-9. doi: 10.1016/j.ygyno.2004.11.043.
9
[Reinduction of paclitaxel therapy after a successfully treated hypersensitivity reaction].[成功治疗过敏反应后重新诱导使用紫杉醇治疗]
Orv Hetil. 2002 Sep 22;143(38):2189-91.
10
Hypersensitivity reactions in paclitaxel treatment of ovarian cancer patients.紫杉醇治疗卵巢癌患者时的超敏反应
J Obstet Gynaecol. 2002 May;22(3):312-3. doi: 10.1080/01443610220130661.

引用本文的文献

1
Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer.前瞻性研究测试简化紫杉醇预处理方案在早期乳腺癌患者中的应用。
Oncologist. 2021 Nov;26(11):927-933. doi: 10.1002/onco.13960. Epub 2021 Sep 24.
2
Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review.重新审视对紫杉烷类药物的超敏反应:一项全面综述
Clin Rev Allergy Immunol. 2015 Oct;49(2):177-91. doi: 10.1007/s12016-014-8416-0.
3
A retrospective review of the frequency and nature of acute hypersensitivity reactions at a medium-sized infusion center: comparison to reported values and inconsistencies found in literature.
回顾性分析一家中等规模输注中心急性过敏反应的频率和性质:与文献报道值比较及发现的不一致之处。
J Cancer. 2011 Mar 10;2:153-64. doi: 10.7150/jca.2.153.
4
Oral premedication for the prevention of hypersensitivity reactions to paclitaxel.用于预防对紫杉醇过敏反应的口服预防性用药。
Med Oncol. 2008;25(3):274-8. doi: 10.1007/s12032-007-9030-2. Epub 2008 Mar 25.
5
Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.紫杉醇:对其用于非小细胞肺癌的药物经济学综述
Pharmacoeconomics. 2001;19(11):1111-34. doi: 10.2165/00019053-200119110-00005.